Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Sep
07
Today In Oncology
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo